Arcus Biosciences, Inc. (RCUS)
24.41
+0.58
(+2.43%)
USD |
NYSE |
Oct 09, 16:00
24.42
+0.01
(+0.04%)
Pre-Market: 20:00
Arcus Biosciences Net Income (Quarterly) : -91.00M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -91.00M |
| March 31, 2026 | -128.00M |
| December 31, 2025 | -106.00M |
| September 30, 2025 | -135.00M |
| June 30, 2025 | 0.00 |
| March 31, 2025 | -112.00M |
| December 31, 2024 | -94.00M |
| September 30, 2024 | -92.00M |
| June 30, 2024 | -93.00M |
| March 31, 2024 | -4.00M |
| December 31, 2023 | -81.00M |
| September 30, 2023 | -71.00M |
| June 30, 2023 | -75.00M |
| March 31, 2023 | -80.00M |
| December 31, 2022 | -67.46M |
| September 30, 2022 | -64.92M |
| June 30, 2022 | -66.63M |
| March 31, 2022 | -67.99M |
| Date | Value |
|---|---|
| December 31, 2021 | 279.37M |
| September 30, 2021 | -77.98M |
| June 30, 2021 | -75.97M |
| March 31, 2021 | -72.59M |
| December 31, 2020 | -51.85M |
| September 30, 2020 | 1.822M |
| June 30, 2020 | -45.07M |
| March 31, 2020 | -27.75M |
| December 31, 2019 | -16.60M |
| September 30, 2019 | -22.35M |
| June 30, 2019 | -28.09M |
| March 31, 2019 | -17.67M |
| December 31, 2018 | -12.30M |
| September 30, 2018 | -10.81M |
| June 30, 2018 | -13.53M |
| March 31, 2018 | -12.95M |
| December 31, 2017 | -13.21M |
| September 30, 2017 | -23.12M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Halozyme Therapeutics, Inc. | 229.91M |
| AVITA Medical, Inc. | -7.663M |
| Iovance Biotherapeutics, Inc. | -47.32M |
| Editas Medicine, Inc. | -18.23M |
| Recursion Pharmaceuticals, Inc. | -131.00M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 41.00M |
| Total Expenses (Quarterly) | 132.00M |
| EPS Diluted (Quarterly) | -0.7216 |
| Enterprise Value | 2.512B |
| Gross Profit Margin (Quarterly) | 95.12% |
| Profit Margin (Quarterly) | -222.0% |
| Earnings Yield | -16.00% |
| Normalized Earnings Yield | -16.00 |